Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:01 UTC. Every row links to its source record.

Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time

Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer

NCT05581589 · University of Washington · PHASE2 · terminated · last registry update 2026-04-27 · Decision brief

No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.

What was said, and by whom

Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.

Kind	Quote	Our category	Source
Stated	“Study closed to accrual before meeting accrual goal due to major enrollment challenges based on the very rare disease indication studied and rapid changes in the therapy landscape.”	–	Registry record, University of Washington

Also happening at the time. Not shown to be a cause.

Registry events on other trials of drugs against TACSTD2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.

What is not public

Internal portfolio and board discussions
Unpublished trial data and interim analyses
Terms of any partner or licence decision